{"id":"nct:NCT06273553","kind":"trial","title":"A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3","authors":["RinuaGene Biotechnology Co., Ltd."],"author_count":1,"year":2024,"published":"2024-02-22","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT06273553","source_url":"https://clinicaltrials.gov/study/NCT06273553","archive_url":"https://space-kitty.com/papers/nct:NCT06273553","updated":"2024-02-22","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The purpose of this study is to to evaluate the safety, tolerability, immunogenicity, and efficacy of RG002 Injection in subjects with HPV16/18 associated Cervical Intraepithelial Neoplasia Grade 2 or 3(CIN2/3).","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Human Papillomavirus Associated Intraepithelial Neoplasia","Cervical Intraepithelial Neoplasia Grade 2/3","Human Papillomavirus Type 16 Infection","Human Papillomavirus Type 18 Infection"],"details":{"acronym":null,"status":"NOT_YET_RECRUITING","phase":"PHASE1, PHASE2","study_type":"INTERVENTIONAL","enrollment":39,"sponsor":"RinuaGene Biotechnology Co., Ltd.","conditions":["Human Papillomavirus Associated Intraepithelial Neoplasia","Cervical Intraepithelial Neoplasia Grade 2/3","Human Papillomavirus Type 16 Infection","Human Papillomavirus Type 18 Infection"],"interventions":["BIOLOGICAL: RG002 injection"],"start_date":"2024-03-01","start_date_type":"ESTIMATED","primary_completion_date":"2026-10-01","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"mrna-cancer-vaccines","name":"mRNA Therapeutics & Cancer Vaccines","domain_slug":"medicine"}],"cited_in_dossiers":[]}